Stock Screener App

Frei -

Installieren

21.34

1.70% -0.37

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Phar - marketscreener.com

RARE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - GlobeNewswire Inc.

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire

Ultragenyx’s gene therapy meets co-primary endpoint in Phase III trial - Yahoo

DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit ... - Bluefield Daily Telegraph

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - TradingView

Ultragenyx reveals positive Phase III results for DTX301 AAV8 gene therapy - The Pharmaletter

Russell Investments Group Ltd. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx reports positive Phase 3 data for OTC gene therapy By Investing.com - Investing.com India

Bank of America, Leerink Maintain Buy/Outperform on RARE Ultragenyx March 2026 - Meyka

JP Morgan Lowers Price Target for Ultragenyx Pharmaceutical (RAR - GuruFocus

Ultragenyx reports positive Phase 3 data for OTC gene therapy - Investing.com Australia

ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure ... - Bluefield Daily Telegraph

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $74.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Leerink Partners reiterates Ultragenyx stock rating on trial data - Investing.com Nigeria

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder - Benzinga

Ultragenyx Pharmaceutical Inc Announces Positive 36-Week Data From Phase 3 Study Of DTX301 AAV8 Gene Therapy For The Treatment Of Ornithine Transcarbamylase Deficiency - marketscreener.com

BofA reiterates Ultragenyx stock rating on positive gene therapy data - Investing.com

Leerink Partners reiterates Ultragenyx stock rating on trial data By Investing.com - Investing.com India

Ultragenyx gene therapy posts Phase III win for urea cycle disorder - FirstWord Pharma

Ultragenyx posts trial win for gene therapy (RARE:NASDAQ) - Seeking Alpha

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire

Ultragenyx Announces Positive Phase 3 Results for DTX301 - TipRanks

Ultragenyx (RARE) Sees Positive Phase 3 Results for Gene Therapy - GuruFocus

Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency - The Manila Times

Ultragenyx's gene therapy helps control ammonia levels in late-stage study - marketscreener.com

Ultragenyx Announces Positive 36-Week Data from Phase 3 - GlobeNewswire

RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Assessing Ultragenyx Pharmaceutical (RARE) Valuation After Class Action And Failed Setrusumab Phase III Trials - simplywall.st

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire

Growth Value: What are the future prospects of Ultragenyx Pharmaceutical IncTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn

LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION - Finviz

RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 – Company AnnouncementFT.com - Financial Times

Sands Capital Management LLC Cuts Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire

Insider Sell: Karah Parschauer Sells Shares of Ultragenyx Pharma - GuruFocus

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE - ChartMill

RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire

Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class ActionRARE - PR Newswire

Ultragenyx EVP Pinion sells $228k in shares - Investing.com Nigeria

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says - Law360

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Financial Times

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire

Levi & Korsinsky, LLP: Institutional Investor Notice --- Ultragenyx Pharmaceutical Lead Plaintiff Opportunity - GlobeNewswire

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.6%Still a Buy? - MarketBeat

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

FinancialContentUltragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Richtech Robotics Inc. (RR), Ultragenyx Pharmaceutical Inc. (RARE), and Mereo BioPharma Group plc (MREO) Announced by Holzer & Holzer, LLC - marketscreener.com

CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. - GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mydailyrecord.com

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm - Sahm

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - GlobeNewswire Inc.

Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionRGRD Law - marketscreener.com

Analysis Recap: Can Ultragenyx Pharmaceutical Inc. (UP0) stock stage a strong rebound this quarter2025 Trade Ideas & Community Verified Trade Alerts - Naître et grandir

Ultragenyx Pharmaceutical Inc. $RARE Stock Position Increased by Blue Owl Capital Holdings LP - MarketBeat

RPRX

$45.65

0.48%

ROIV

$28.06

1.72%

MRNA

$52.56

1.55%

BNTX

$91.19

1.21%

INSM

$139.50

0.01%

ONC

$284.05

0.44%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters